D81.30 Adenosine deaminase deficiency, unspecified

Name of the Condition

• Adenosine deaminase deficiency, unspecified

Summary

Adenosine deaminase (ADA) deficiency, unspecified, is a rare inherited disorder that impairs the immune system, leading to severe combined immunodeficiency (SCID). This condition results from genetic mutations that reduce or eliminate the activity of the ADA enzyme, disrupting the development and function of lymphocytes (T cells, B cells, and natural killer cells). The deficiency causes a buildup of toxic metabolites, which damage immune cells and impair the body's ability to fight infections. Without treatment, ADA deficiency is typically fatal in early childhood due to recurrent, severe infections.

Causes

ADA deficiency is caused by genetic mutations in the ADA gene, which provides instructions for producing the adenosine deaminase enzyme. These mutations disrupt the enzyme's function, leading to the accumulation of toxic substances that destroy lymphocytes. The condition is inherited in an autosomal recessive pattern, meaning an individual must inherit two mutated copies of the gene (one from each parent) to develop the disorder. Carriers (those with one mutated copy) typically do not show symptoms.

Risk Factors

• Genetic predisposition, often with a family history of immunodeficiency disorders.
• Consanguinity (parents who are closely related) increasing the risk of autosomal recessive forms.
• Certain ethnic backgrounds with higher prevalence of specific genetic mutations.

Symptoms

• Recurrent, severe, or persistent infections (e.g., bacterial, viral, fungal).
• Failure to thrive or delayed growth in infants and children.
• Chronic diarrhea or gastrointestinal issues.
• Skin rashes or infections.
• Persistent thrush (oral candidiasis).
• Respiratory infections (e.g., pneumonia, bronchitis).

Diagnosis

Diagnosis involves a combination of clinical evaluation, laboratory testing, and genetic analysis. Blood tests may show low lymphocyte counts or abnormal immune function. Enzyme activity assays can measure ADA levels, and genetic testing confirms mutations in the ADA gene. Newborn screening for SCID may also detect ADA deficiency early.

Treatment Options

Treatment focuses on restoring immune function and may include enzyme replacement therapy (PEG-ADA), hematopoietic stem cell transplantation (HSCT), or gene therapy. Supportive care, such as antibiotics for infections and immunoglobulin replacement, is often necessary. Early intervention improves outcomes.

Prognosis and Follow-Up

With early diagnosis and treatment, prognosis improves significantly. HSCT or gene therapy can provide long-term immune reconstitution, though complications like graft-versus-host disease may occur. Lifelong monitoring for infections and immune function is essential.

Complications

• Recurrent severe infections leading to organ damage.
• Failure to thrive or developmental delays.
• Increased risk of malignancies due to impaired immune surveillance.
• Complications from treatment, such as graft rejection or infection.

Lifestyle & Prevention

• Avoid exposure to infections (e.g., crowds, sick contacts).
• Practice good hygiene (handwashing, vaccination for household members).
• Follow prescribed treatments and monitor for symptoms.
• Genetic counseling for families with a history of the disorder.

When to Seek Professional Help

Seek immediate medical attention for:

• Fever or signs of infection (e.g., cough, diarrhea).
• Unusual fatigue or poor growth in infants.
• Persistent skin rashes or thrush.
• Any new or worsening symptoms.

Tips for Medical Coders

Document the specific type of ADA deficiency (e.g., partial vs. complete) and any associated complications. Ensure clinical documentation supports the diagnosis, including laboratory or genetic test results. Use this code for unspecified ADA deficiency when more detailed information is not available.